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The vaccinia virus (VACV) complement control protein (VCP) is an immunomodulatory protein that is both
secreted from and expressed on the surface of infected cells. Surface expression of VCP occurs though an interaction
with the viral transmembrane protein A56 and is dependent on a free N-terminal cysteine of VCP. Although A56 and
VCP have been shown to interact in infected cells, the mechanism remains unclear. To investigate if A56 is sufficient
for surface expression, we transiently expressed VCP and A56 in eukaryotic cell lines and found that they interact
on the cell surface in the absence of other viral proteins. Since A56 contains three extracellular cysteines, we
hypothesized that one of the cysteines may be unpaired and could therefore form a disulfide bridge with VCP. To
test this, we generated a series of A56 mutants in which each cysteine was mutated to a serine, and we found that
mutation of cysteine 162 abrogated VCP cell surface expression. We also tested the ability of other poxvirus
complement control proteins to bind to VACV A56. While the smallpox homolog of VCP is able to bind VACV A56,
the ectromelia virus (ECTV) VCP homolog is only able to bind the ECTV homolog of A56, indicating that these
proteins may have coevolved. Surface expression of poxvirus complement control proteins may have important
implications in viral pathogenesis, as a virus that does not express cell surface VCP is attenuated in vivo. This
suggests that surface expression of VCP may contribute to poxvirus pathogenesis.
Poxviruses, including vaccinia virus (VACV), encode large
numbers of immunomodulatory proteins that help them estab-
lish an infection and combat the host’s immune response (10,
32). One of these is the vaccinia virus complement control
protein (VCP), which is both secreted from and expressed on
the surface of infected cells (9, 14, 16, 17). VCP acts against the
complement system, a series of soluble proteins that is an
important early component of the innate immune system and
also shapes adaptive immune responses (15, 42, 43). In re-
sponse to viral infection, complement can opsonize or inacti-
vate virions and can lyse enveloped virus or infected cells (1, 3,
7, 12). Because of these pressures, a number of viruses, includ-
ing herpes simplex virus, flaviviruses, and poxviruses, encode
novel or host-derived regulators of complement, while others,
including HIV and poxviruses, incorporate host complement
regulatory proteins into virus particles (7, 11, 31, 39). Many
orthopoxviruses encode a complement regulator (8, 20, 23, 29),
and the most studied of these is VCP. Structurally, VCP is
made up of four short consensus repeats (SCR) that are the
basic units of mammalian complement regulators (17, 25), and
VCP has been shown to interfere with the complement cascade
at multiple steps (2, 16, 20–22, 25, 28–30, 33). Additionally, a
VCP knockout virus generates smaller lesions in animal mod-
els (14, 16). While some host complement control proteins
(CCPs) are secreted, many contain transmembrane domains
(or a glycophosphatidylinositol anchor) and are thus expressed
on the cell surface (42, 43). Thus, when we found that VCP is
also expressed on the infected cell surface and protects in-
fected cells from complement-mediated lysis in vitro (9), we
believed this to be an important interaction that required fur-
ther investigation. We previously found that the N-terminal
cysteine on VCP was needed for surface expression and that
the VACV transmembrane protein A56 was also required (9).
The vaccinia virus A56 protein is a type 1 transmembrane
glycoprotein that is found on the surface of infected cells and
on extracellular virus particles (4, 18, 26, 27, 36). It interacts
with another viral protein, K2 (19, 37, 45), which lacks a trans-
membrane domain and binds to A56 noncovalently (36). The
A56/K2 complex prevents syncytium formation between in-
fected cells and superinfection by interacting with the vaccinia
virus entry/fusion complex on virions (24, 38, 40, 41). Here we
provide evidence that the N-terminal cysteine on VCP forms
an intermolecular disulfide bond with cysteine 162 on the
ectodomain of A56. We also demonstrate that similar interac-
tions can occur with other poxvirus CCPs, as the smallpox virus
and ectromelia virus homologs of VCP also exhibit A56-de-
pendent surface expression.
MATERIALS AND METHODS
Cells and viruses. BSC-1, 293T, and RK-13 cells were grown and maintained
in minimum essential media (MEM) supplemented with 10% fetal bovine serum
(FBS). Viruses were grown and titers were determined in BSC-1 in MEM with
2.5% FBS. The generation and isolation of vaccinia virus VCP knockout (vv-
VCPko), vaccinia virus with a mutated VCP lacking the free N-terminal cysteine
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(vv-VCPmut), and vaccinia virus-VCP wild type (vv-VCPwt) from the parental
stain WR has been described previously (9). The VCP rescue virus (VCPrescue)
was made by reinserting the VCP open reading frame (ORF) under its native
promoter into the VCPko virus. After the initial infection of cells with VCPko
and transfection with a plasmid containing the wild-type VCP ORF, the progeny
virus was amplified on BSC-1 cells, and the cell lysate was used to infect fresh
RK-13 cells. After 24 h of infection these cells were stained for VCP with the
anti-VCP monoclonal antibody (MAb) 3F11 and an anti-mouse APC secondary
Ab under nonpermeabilized conditions, and positive cells were collected through
live cell sorting. The resulting cells were lysed, the virus was plaque purified three
times on BSC-1 cells, and a stock of virus was grown and purified. PCR con-
firmed proper insertion of the gene back into the C3L position and that no
mutations occurred during PCR amplification or virus isolation. Expression of
VCP in the rescued virus was confirmed by Western blotting and fluorescence-
activated cell sorting (FACS) analysis.
Cloning of poxvirus genes into expression plasmids. The previously generated
plasmids containing the ORF of VCP and VCPmut (9), as well as the CCP
proteins expressed by variola virus (smallpox virus inhibitor of complement
enzymes [SPICE]), ectromelia virus (ECTV; ectromelia virus inhibitor of com-
plement enzymes [EMICE]), and monkeypox virus (MPXV; monkeypox virus
inhibitor of complement enzymes [MoPICE]) (20), were used to insert the ORFs
into pCAGGS. The VACV A56 ORF was PCR amplified from VACV (strain
WR) and initially cloned into TOPO 2.1 by using the primers 5-CGG GGT ACC
ATG ACA CGA TTA CCA ATA CTT TTG-3 and 5-CGC GCG GCT ACG
CTA GAC TTT GTT CT-3. This plasmid was then used to generate A56mut1,
-mut2, and -mut3 by site-directed mutagenesis using overlapping primers.
A56mut1 primers were 5-GCA ACT CTA TCA TCT AAT CGA AAT AAT
ACA AAT G-3 and 5-CAT TTG TAT TAT TTC GAT TAG ATG ATA GAG
TTG C-3; A56mut2 primers were 5-GCC GGT ACT TAT GTA TCT GCA
TTC TTT ATG ACA TC-3 and 5-GAT GTC ATA AAG AAT GCA GAT
ACA TAA GTA CCG GC-3; A56mut3 primers were 5-GAT TAT ATA GAT
AAT TCT AAT TCC TCG TCG GTA TTC G-3 and 5-CGA ATA CCG ACG
AGG AAT TAG AAT TAT CTA TAT AAT C-3. A56mut12 was created by
site-directed mutagenesis of A56mut1 using the primers for mut2. All four
mutated ORFS were then inserted into pCAGGS. The ectromelia virus A56
homolog was PCR amplified from the ECTV Moscow strain (primers 5-CGG
GGT ACC ATG GCA CGA TTG TCA ATA CTT TTG-3 and 5-CGC GCG
GCT AGC CTA GAC TTT GTT CTC TGT TTT G-3) and the monkeypox virus
A56 homolog PCR amplified from MPXV Zaire and cloned into TOPO2.1 prior
to insertion into pCAGGS (forward primer, 5-CGG GGT ACC ATG ACA
CAA TTA CCA ATA CTT TTG-3; the reverse primer was the same as that for
ECTV A56). K2 was cloned from VACV (strain WR) with the addition of a
C-terminal hemagglutinin (HA) tag using the primers 5-CGG GGT ACC ATG
ATT GCG TTA TTG ATA CTA TCG-3 and 5-CGC CGA TCG TTA GGC
ATA ATC GGG AAC ATC GTA GGG GTA AGA GCC ACC GCC ACC
AGG AGA TTC CAC CTT ACC CAT AAA C-3. The ORFs in all final
plasmids were sequenced to confirm that sequences (or site-directed point mu-
tations) were correct.
Transfection of poxvirus genes and flow cytometry. Plasmid transfections were
performed in six-well plates of 95% confluent 293T cells by using Lipofectamine
and serum-free medium. Two micrograms of each plasmid was used per well,
along with 10 l of Lipofectamine. Forty-eight hours later, the cells were lifted
in FACS buffer (phosphate-buffered saline [PBS] without Ca2/Mg2 and with
1% FBS and 0.04% sodium azide) and transferred to FACS tubes. Cells were
then incubated with anti-VCP Ab (either mouse MAb 3F11 [13, 40] or a rabbit
polyclonal antibody [20]) and anti-A56 Ab (either MAb LC10 or a previously
described peptide-raised rabbit polyclonal antibody [40]) at 1:1,000 dilutions.
After washing, the cells were incubated with appropriate fluorescein isothiocya-
nate-conjugated or allophycocyanin (APC)-conjugated anti-mouse or anti-rabbit
antibodies at a 1:40 dilution and then fixed using 3% paraformaldehyde (PFA).
The cells were then read on a FACScalibur and analyzed using FlowJo. Scatter
plots were gated on live cells using forward and side scatter. Histograms were
created by gating on cells that were A56 positive. For the K2 FACS, collected
cells were incubated with the rabbit anti-A56 Ab and a previously described K2
MAb, 4A11-4A3 (5).
Affinity isolation of tagged A56 from infected cells. To determine how much
VCP associates with A56, we infected cells with a previously described recom-
binant VACV expressing a tagged A56 (40). BSC-1 cells were infected with
vA56TAP or a virus expressing an untagged A56 (vv-VCPwt). After 48 h, cell
lysates were harvested in radioimmunoprecipitation assay buffer and incubated
with streptavidin-Sepharose beads for 1 h at 4°C. After washing and eluting the
protein, Western blots were performed using a rabbit polyclonal anti-A56 anti-
body and the mouse monoclonal anti-VCP antibody 3D1 (13).
Infection of cells for FACS or immunofluorescence. For VACV and ECTV
infection of cells for cell sorting, RK-13 cells were infected in wells of a six-well
plate for 24 h with ectromelia virus, vv-VCPwt, or vv-VCPko. The cells were then
collected, transferred to FACS tubes, and stained with a rabbit anti-VCP Ab and
the mouse anti-A56 MAb as described above. For immunofluorescent images of
MPXV-infected cells, BSC-40 cells in eight-well chamber glass slide (Nunc) at
50% confluence were infected with 1 PFU/cell of either VACV, MPXV USA,
or MPXV Congo and incubated for 18 h in a 6% CO2 incubator at 35.5°C. After
a PBS wash, the cells were fixed for 30 min with 2% PFA in PBS, followed by
washes and blocking with 5% bovine serum albumin (BSA) in PBS for 1 h 30 min
at room temperature (RT). Cells were then stained for 2 h at RT with anti-VCP
mouse monoclonal antibody 2E5 at a 1:40 dilution in 5% BSA. After PBS
washes, wells were incubated in the dark for 2 h at RT with Alexa Fluor 488 goat
anti-mouse IgG (Invitrogen) at 1:200 in 5% BSA. Wells were washed and
mounted in VectaShield hard-set mounting medium containing 4,6-diamidino-
2-phenylindole, and images were taken at 400 magnification under oil immer-
sion.
Mice for intranasal and intradermal infections. For all mouse experiments, 6-
to 8-week-old female C57BL/6 mice were purchased from the Jackson Labora-
tory and housed in a specific-pathogen-free facility at the University of Pen-
nsylvania. For intranasal infections, mice (five per group) were infected with 103,
104, or 105 PFU of the indicated viruses, and weight loss was measured as has
been previously described (44). For intradermal infections, groups of mice were
anesthetized and inoculated in both ear pinnae with 10 l of the indicated virus
diluted to 2  103 PFU/l in PBS (2  104 PFU/ear) using a 29-gauge insulin
syringe (BD). Mice were monitored for lesion development, and lesions greater
than 1 mm in diameter were measured using digital calipers. Experiments were
conducted in accordance with the guidelines of the University of Pennsylvania
Institutional Animal Care and Use Committee.
Statistical analysis. Statistical analysis was performed using the Prism pro-
gram (GraphPad). Unpaired Student’s t tests were used to compare differences
in weight or lesion size between two groups, and a two-way analysis of variance
(ANOVA) was used to compare differences in lesion sizes between three groups.
RESULTS
VCP cell surface expression is dependent on A56 and does
not require other viral proteins. Previously, our lab showed
that expression of VCP on the infected cell surface is mediated
by an interaction with the viral A56 protein and requires a free
N-terminal cysteine on VCP (9). To investigate if A56 is suf-
ficient for VCP surface expression, we transiently transfected
cells with plasmids expressing VCPwt, VCPmut, or wild-type
A56 (A56wt). We found that when VCPwt is transfected into
293T cells, it is not expressed on the cell surface (Fig. 1A).
However, when VCPwt and A56wt are cotransected, VCP is
expressed on the surface of cells that are also A56 positive (Fig.
1B). Importantly, cell surface expression is lost when VCPmut
is transfected with A56wt (Fig. 1C), indicating that the tran-
sient-transfection system reproduces what we saw in cells that
were infected with virus expressing either VCPwt or VCPmut
(9). In transfected cells that are A56 positive, a 2-log10 shift in
mean fluorescence intensity (MFI) was seen between VCPwt
and VCPmut (Fig. 1D).
In native Western blot assays, A56 is found as a monomer
and a higher-molecular-weight band (40) (data not shown).
The existence of a strong monomer band suggests that a sur-
plus of A56 exists relative to the amount of K2 and VCP on the
surface of cells. To begin to assess how much VCP is bound to
A56, a recombinant VACV expressing a TAP-tagged version
of A56 (40) was used to coprecipitate VCP. We found that
when tagged A56 was pulled down with streptavidin-Sepharose
beads, VCP coprecipitated (Fig. 1E). However, only a small
amount of VCP was present relative to the amount of A56-
TAP and to the proteins from the input infected cell lysates.
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This suggests that a surplus of A56 exists relative to the amount
of VCP on the surface of cells.
Cysteine 162 of A56 is required for VCP cell surface expres-
sion. The fact that VCP required its N-terminal cysteine to
bind A56 suggested to us that either a disulfide-bonded VCP
homodimer (20) interacted with A56 to allow surface expres-
sion or that the free cysteine on monomeric VCP formed a
disulfide bridge with an unpaired cysteine in the A56 ectodo-
main. To investigate which model best explained the interac-
tion of VCP with A56, we mutated each of the three cysteine
residues in the ectodomain of A56. Each cysteine was mutated
to a serine residue, and the resulting expression plasmids were
named A56mut1, A56mut2, and A56mut3, respectively (Fig.
2A). If an intermolecular bridge were required for surface
FIG. 1. VCP and A56 interact on transfected and infected cells. VCP, VCPmut, and A56wt were transfected into 293T cells either alone or in
combination. After 48 h, the cells were collected and stained under nonpermeabilized conditions for FACS analysis with an anti-VCP polyclonal
antibody and anti-56 MAb LC10. (A) VCP is not expressed on the cell surface when transfected alone. (B and C) VCP, but not VCPmut, is
expressed on the cell surface in the presence of A56. (D) Levels of VCP expression on A56-positive cells. The black solid line represents cells
transfected with VCP and A56wt; the gray shaded area represents cells transfected with VCPmut and A56wt. (E) VCP is present after pulling down
A56-TAP with streptavidin from cells infected with virus expressing TAP-tagged A56 (A56-TAP). Western blots were probed with anti-A56 and
anti-VCP antibodies to show the presence of the indicated proteins. Boxed areas on the left represent blots of the input cell lysate from cells
infected with virus expressing A56-TAP. Boxed areas on the right represent blots of the proteins pulled down with streptavidin from cells infected
with virus expressing untagged A56 (WT) or from cells infected with virus expressing TAP-tagged A56.
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FIG. 2. A56 mutagenesis and VCP surface expression. (A) Schematic of the cysteine pattern in the ectodomain of A56 and the three cysteine
mutant A56 proteins. (B) Expression levels of A56wt versus A56mut1, A56mut2, A56mut3, and A56mut12. (C) Cells positive for A56 expression
were gated and analyzed for VCP expression. Mean fluorescence intensity (MFI) levels are listed in the table to the right of the figure. VCP was
cotransfected with the indicated A56 construct and stained with anti-VCP MAb 3F11, anti-A56 rabbit Ab, and appropriate secondary Abs and
analyzed.
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expression of VCP, the loss of VCP’s cysteine partner on A56
would prevent VCP expression on the cell surface. While the
anti-A56 MAb LC10 used in Fig. 1 could detect A56mut3, it no
longer recognized A56mut1 or A56mut2 (data not shown),
indicating that the MAb LC10 recognizes a conformation
epitope that is lost when either Cys34 or Cys103 is mutated.
However, when we used a rabbit polyclonal Ab raised to a
peptide in the A56 ectodomain (40), all three mutants were
recognized and were expressed at the cell surface at levels
similar to A56wt (Fig. 2B). This indicates that the conforma-
tional epitope lost in A56mut1 and A56mut2 did not result in
drastic misfolding and loss of the trafficking of A56 mutants to
the cell surface. Each of the mutants was examined for the
ability to interact with VCP and result in surface expression of
VCP. When VCP was cotransfected with either A56mut1 or
A56mut2, the level of VCP cell surface expression was similar
to cells cotransfected with A56wt (Fig. 2C). A double mutant
(A56mut12) is also able to interact with VCP and result in
surface expression at levels similar to A56wt (data not shown).
These results indicate that Cys34 and Cys103 are not required
for VCP to interact with A56. However, when cells are cotrans-
fected with A56mut3, VCP is not found on the cell surface and
has an expression profile similar to VCPmut plus A56wt (Fig.
2C). This demonstrates that surface expression is lost even
when the free N-terminal cysteine on VCP is present and
homodimers can form. Taken together, these experimental
results support a model in which cell surface expression of
VCP is dependent on formation of a disulfide bridge between
VCP and A56.
A56mut3 retains the ability to bind K2. It is possible that
mutating Cys162 of A56 could cause misfolding of the protein,
resulting in the lack of VCP interaction with A56mut3. There-
fore, we examined the ability of A56mut3 to interact with the
viral K2 protein, which binds to A56 noncovalently. As was
previously shown by the Moyer group (36), transfecting K2
alone does not result in cell surface expression of K2 (data not
shown). Also as previously reported (36, 41), we found that K2
is expressed on the surface of cells in the presence of A56wt
(Fig. 3). We also found that in the presence of A56mut3, K2 is
still expressed on the surface of cells at the same level as with
A56wt. These data suggest that mutating Cys162 specifically
abrogates the A56-VCP interaction without affecting the inter-
action between A56 and K2.
The variola virus VCP ortholog binds the vaccinia virus A56
protein. The unpaired N-terminal cysteine in VCP is conserved
in many VCP orthologs, including the CCP proteins expressed
by variola virus (SPICE) and ectromelia virus (EMICE).
MoPICE has lost this N-terminal cysteine, but due to a trun-
FIG. 3. A56mut3 is able to bind K2. 293T cells were transfected
with A56wt alone or with K2 plus A56wt and A56mut3. The cells were
then stained with anti-K2 MAb 4A11-4A3 and the rabbit anti-A56Ab.
A56-positive cells were gated and used to create the histogram.
FIG. 4. Comparison of orthopoxvirus A56 genes. The protein sequences of vaccinia virus (VACV-WR) A56 and the homologs in variola virus
(VARV-Bangladesh), monkeypox virus (MPXV-Zaire), and ectromelia virus (ECTV-Moscow) were downloaded from poxvirus.org and aligned
using BLAST. Shaded residues indicate identical amino acids to vaccinia virus, and dashes represent missing amino acids. Conserved cysteines in
the ectodomain are indicated in bold and with an arrow. The putative transmembrane domain is marked with the black line above the residues.
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cation right after the start of the fourth SCR it has an unpaired
cysteine near its C terminus (6, 20). Additionally, all of these
viruses contain a homolog to the vaccinia virus A56 protein,
and interestingly, all of these A56 orthologs retain the three
extracellular cysteines (Fig. 4). Therefore, we hypothesized
that the interaction between A56 and poxvirus CCPs may not
be limited to VACV. To test this, we first studied the ability of
SPICE to interact with VACV A56. We found that SPICE
bound to vaccinia virus A56 (Fig. 5A). We also found that
SPICE, like VCP, is not expressed on the cell surface when
cotransfected with A56mut3 (Fig. 5B). This suggests that
SPICE and A56 can interact on the cell surface through a
disulfide bridge at Cys162, similar to VCP and A56.
EMICE, but not MoPICE, binds to its cognate A56 homolog
efficiently. While VCP and SPICE have identical first SCR
domains, EMICE has 12 amino acid differences in its first
SCR. Cotransfection of EMICE with vaccinia virus A56 pro-
duced weak EMICE surface staining (Fig. 5C). However, stain-
ing of cells infected with ECTV showed that surface staining of
EMICE was clearly evident (Fig. 5D) and that EMICE expres-
sion was similar to VCP expression on vaccinia virus-infected
cells (Fig. 5D). This suggested to us that EMICE can interact
FIG. 5. SPICE and EMICE are also expressed on the cell surface in the presence of A56. SPICE is expressed on cells cotransfected with
vaccinia virus A56wt. (A) Scatter plot of SPICE cotransfected with A56wt. (B) Histogram of SPICE expression on A56-positive cells. The black
line is SPICE transfected with vaccinia virus A56wt, and the shaded gray area is SPICE transfected with A56mut3. (C) Scatter plot of EMICE
transfected with VACV A56. (D) Histogram of CCP expression on virus-infected cells. RK-13 cells were infected with ECTV, VACV, or vv-VCPko
and then stained with a polyclonal anti-VCP antibody. Shown is a histogram of surface staining due to EMICE (black line), VACV (dotted line),
or vv-VCPko (gray shaded area). (E) Scatter plot of EMICE cotransfected with ECTV A56. (F) Histogram of EMICE expression of cells
cotransfected with ECTV A56 (black line), VACV A56 (dotted line), or VACV A56mut3 (gray shaded area).
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with its A56 cognate, but not vaccinia virus A56. To address
this possibility, we cloned the ECTV homolog of A56 (ECTV-
A56) and cotransfected it with EMICE. We found that while
VACV-A56 and ECTV-A56 were expressed on approximately
the same number of cells (19.2% versus 19.8%), EMICE was
expressed to a much higher level at the cell surface when
cotransfected with ECTV-A56 (Fig. 5E). The peak level of
EMICE staining on cells transfected with ECTV-A56 was 2
logs higher than EMICE transfected into cells with VACV-
A56 or VACV-A56mut3 (Fig. 5F). This shift in staining mir-
rors the expression levels of VCP when it is transfected with
vaccinia virus A56.
The monkeypox homolog of VCP, MoPICE, differs from
these other poxvirus CCPs in several respects. As has been
reported elsewhere, MoPICE does not have a free N-terminal
cysteine, as this initial residue is a tyrosine (20). Also, MoPICE
only contains three SCRs due to a point mutation that results
in a truncation after the start of the fourth SCR. Interestingly,
this truncation results in an unpaired cysteine near the C ter-
minus, through which MoPICE can form homodimers (20).
Immunofluorescence of cells infected with MPXV Congo
shows weak cell surface staining of MoPICE compared to
vaccinia virus-infected cells (Fig. 6A). Consistent with the
lower level of surface expression compared to VCP expression
on vaccinia virus-infected cells, cotransfection of MPXV A56
with MoPICE also resulted in low-level surface expression of
MoPICE (Fig. 6B and C), with only 2.48% of cells double
positive. These data suggest that MoPICE is not expressed at
high levels on infected or transfected cells. Taken with the
EMICE data, it appears that the first SCR domain with an
N-terminal free cysteine is crucial for optimal binding to A56.
Vaccinia virus expressing VCPmut is attenuated in vivo. The
N-terminal cysteine residue in VCP is conserved among other
PICEs and has been shown to mediate both cell surface ex-
pression and dimerization of VCP (9, 20). Both cell surface
expression and dimerization of recombinant VCP have been
shown to enhance its complement regulatory function in vitro
(20). In order to determine if cell surface expression and/or
dimerization contribute to VCP’s function as a virulence fac-
tor, we assessed the virulence of our recombinant VACVs
FIG. 6. MoPICE is expressed on the cell surface at low levels. (A) Immunofluorescence of infected cells. BSC-40 cells were infected for 18 h
with MPXV-Congo, VACV, or a CCP-minus strain of MPXV, MPXV-USA, and fixed and stained using anti-VCP MAb 2E5 and fluorescent
secondary Ab. To better visualize the cell distribution of VCP or MoPICE, the white box indicates the area of the image that was enlarged (shown
in the second row of images), but unaltered. (B) Scatter plot of MoPICE cotransfected with MPXV A56. (C) Histogram of MoPICE expression
on A56-positive cells. MoPICE was cotransfected with MPXV-A56 (black line) or VACV A56mut3 (gray shaded area), and cells were then stained
for FACS with polyclonal rabbit anti-VCP and anti-A56 MAb.
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using two mouse models of VACV pathogenesis (Fig. 7). We
first compared vv-VCPmut to vv-VCPko and vv-VCPrescue
after intranasal inoculation. At the lowest dose (103 PFU), all
of the mice survived, but mice infected with vv-VCPrescue lost
slightly more weight (Fig. 7A). The difference in weight loss
between vv-VCPrescue and the other two viruses was signifi-
cant at days 7 and 8. At the intermediate dose (104 PFU), all
of the mice infected with the VCP rescue virus died, while mice
infected with VCPko or VCPmut lost approximately the same
amount of weight (Fig. 7B). At a high dose (105 PFU), all of
the animals lost weight at a similar rate and died (data not
shown). These experiments show that after intranasal inocula-
tion a virus expressing wild-type VCP is more pathogenic than
viruses with VCP deleted or ones lacking the N-terminal cys-
teine on VCP (and thus unable to form homodimers and/or be
expressed on the cell surface). Interestingly, by this route of
infection, vv-VCPko and vv-VCPmut had similar virulence. We
also examined pathogenesis of vv-VCPko and vv-VCPmut by
using an intradermal model of infection (34, 35). We initially
showed that vv-VCPko made smaller ear lesions than vv-
VCPwt (and vv-VCPrescue) (Fig. 7C). We then infected mice
intradermally with a recombinant VACV encoding VCP lack-
ing the free N-terminal cysteine (vv-VCPmut) and compared
lesion sizes formed by this virus to those formed by a virus
encoding wild-type VCP or a virus that lacked VCP (vv-
VCPko) (Fig. 7D). The lesions formed following infection with
vv-VCPmut were larger than those formed by vv-VCPko but
smaller than those formed by vv-VCPwt. These differences in
lesion sizes were statistically significant. The finding that vv-
VCPko is attenuated following intradermal infection in mice
confirms that VCP contributes to pathogenesis and is similar to
what was reported in the past in rabbits and guinea pigs (14).
Furthermore, as opposed to the intranasal route of inocula-
tion, by which VCPko and VCPmut were similarly attenuated,
by the intradermal route vv-VCPmut formed lesions of an
intermediate size between vv-VCPko and vv-VCPwt. This sug-
gests that the ability of VCP to bind to the cell surface and/or
dimerize contributes to pathogenesis.
DISCUSSION
VCP has been previously characterized as the major protein
secreted from VACV-infected cells (16, 17) and has only re-
cently found to also be expressed on the infected cell surface
(9). The N-terminal cysteine of VCP is necessary for surface
expression; however, the precise mechanism by which VCP
interacted with A56 was unknown. We found that the primary
method for VCP surface expression is through a disulfide
bridge with Cys162 of the viral A56 protein. Mutation of A56
Cys34 and/or Cys103 results in loss of recognition by an anti-
A56 monoclonal antibody, LC10. However, despite the loss of
recognition by this antibody, these mutated proteins can still
traffic to the cell surface and interact with VCP. Our work
therefore also provides important information about A56.
While cysteines 34 and 103 of A56 are unnecessary to bind
VCP, they may play a role in the folding of A56. The N-
terminal domain of A56 has homology to the Ig superfamily,
which is heavily disulfide bonded. It is possible that the first two
cysteines in A56 form an intramolecular bridge that, when
mutated, alters an epitope recognized by MAb LC10, but the
mutated protein still maintains sufficient folding to allow the
protein to properly traffic to the cell surface.
VCP forms a disulfide bond with Cys162 of A56, and we
have shown that this specific interaction also occurs with other
poxviruses proteins, like SPICE. Soluble SPICE is capable of
the same catalytic activity as VCP, but with a 100- to 1,000-fold
increase in activity against human complement (21, 29, 33).
FIG. 7. Wild-type VCP is needed for full virulence in mice. Our
panel of recombinant viruses was studied in 6- to 8-week-old female
C57BL/6 mice either after intranasal (A and B) or intradermal (C and
D) inoculation. (A and B) Average weight loss of 6-week-old mice
(n 5 for all groups) infected with vaccinia virus encoding VCPrescue,
VCPmut, or VCPko at 103 PFU (A) or 104 PFU (B). #, indicates that
all mice infected with vv-VCPrescue died; †, a single mouse in the
group infected with vv-VCPko died; , significant difference (P 0.05)
on the days indicated between VCPrescue and VCPko and between
VCPrescue and VCPmut (unpaired Student’s t test). (C and D) Lesion
diameters in 6- to 8-week-old mice inoculated with 2  104 PFU of
VCPrescue, VCPwt, or VCPko (C) or VCPwt, VCPko, or VCPmut
(D). For panel C, data points represent the mean lesion diameter 
standard error of the mean of 10 infected ears per group (two ears per
mouse). P values for the difference between VCPko and VCPwt and
between VCPko and VCPrescue for each day are as follows: , P 
0.05; , P  0.01; @, P  0.001 (unpaired Student’s t test). For panel
D, data points represent the mean lesion diameter standard error of
the mean of 20 (VCPko), 14 (VCPwt), or 10 (VCPmut) infected ears
per group (two ears per mouse). Differences in lesion size between the
groups of mice were statistically significant (P  0.01; two-way
ANOVA).
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Therefore, it is interesting to speculate that expression of
SPICE on the infected cell surface may contribute to its sig-
nificant pathogenesis in humans. Another significant finding is
the interaction between the ectromelia virus homolog of VCP
and A56. EMICE, in contrast to SPICE, is only able to interact
efficiently with its own homolog of A56. This raises the intrigu-
ing possibility that coevolution occurred for these two proteins,
as EMICE and ectromelia virus A56 are less similar to the
vaccinia virus proteins than their variola virus counterparts.
Conversely, the lack of high surface expression of MoPICE
may mean that efficient cell surface expression of MoPICE is
not possible without an N-terminal cysteine, even in the pres-
ence a C-terminal free cysteine. This is interesting, because it
has been shown that this free C-terminal cysteine can form
homodimers in a similar fashion as the orthologs with a free
N-terminal cysteine (20).
We have also shown that a virus that cannot express cell
surface VCP is modestly attenuated in vivo. This finding, com-
bined with earlier in vitro data showing that, compared to cells
infected with a VCP deletion virus, wild-type vaccinia virus-
infected cells are resistant to complement-mediated lysis (9),
suggests that the ability of VCP to interact with A56 and be
expressed on the cell surface may have important implications
for poxvirus pathogenesis. After ear pinnae infection, VCPmut
formed larger lesions than VCPko. This was not entirely un-
expected, since the majority of VCP is a secreted monomer.
Therefore, when VCP is mutated so that it cannot form ho-
modimers and/or be expressed on the cell surface, VCP still
has complement regulatory activity. However, since mutating
the N-terminal cysteine also abrogates dimerization of VCP,
the contribution of secreted VCP homodimers to the attenu-
ated lesion size we observed is not known. Our biochemical
analysis of the interaction between VCP and A56 has identified
a mutation in A56 that disrupts the A56-VCP interaction with-
out disrupting the A56-K2 complex. Comparing pathogenesis
of vv-VCPmut with a recombinant virus expressing A56mut3
will allow us to define the roles of surface-bound VCP and
dimeric VCP in poxvirus pathogenesis. As opposed to the
intradermal route of infection, where we found statistically
significant differences between lesions formed by VCPko and
VCPmut, these viruses appeared to be similarly attenuated
after intranasal inoculation of mice. This may indicate that in
a lung pneumonia model, the contribution of cell surface ex-
pression and/or the formation of the VCP homodimer is im-
portant for VCP’s contribution to pathogenesis. Again, work
with a recombinant virus expressing A56mut3 will allow us to
define the roles of surface-bound VCP and dimeric VCP in
poxvirus pathogenesis.
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